Alpiropride
Alpiropride (INN ; brand name Revistel, Rivistel, or Rivestel) is a dopamine D2 receptor antagonist of the benzamide group related to sulpiride.[1][2][3][4][5] It is described as an antihypertensive agent and has been marketed for use as an antimigraine medication in Portugal.[1][4][2] The drug was first described by 1980[1] and was introduced for medical use by 1989.[4] It remained marketed in Portugal as late as 2000.[2] References
|